Studies of safety, infectivity and immunogenicity of a new temperature-sensitive (ts) 51-1 strain of Salmonella typhi as a new live oral typhoid fever vaccine candidate.
This report describes the results of a phase 1 study evaluating the safety, infectivity, and immunogenicity of a new live oral Salmonella typhi temperature-sensitive (ts) 51-1 typhoid fever vaccine in the human. Three normal male subjects aged 23-32 years received three oral doses of S. typhi ts 51-1, each dose containing 10(9) organisms. Prior to and following immunization each subject was carefully monitored by clinical and laboratory parameters over a 2 week period during which serial specimens of blood and stool were analysed for the presence of the organism. Blood specimens were also obtained for the determination of serum antibody and cell-mediated immune responses and stool filtrates were analysed for the development of coproantibody. The results of these studies indicate that: (1) the vaccine is well tolerated with no clinical or laboratory evidence of adverse reactions; (2) ts 51-1 was detected in only one stool specimen from one volunteer; the organism recovered displayed characteristics of the ts 51-1 vaccine strain; and (3) although no significant humoral or cell-mediated lymphocytotoxic immune responses were detected in the blood, coproantibody was detected in stool specimens from all of the three immunized subjects and IgA-armed ADCC activity was detected in two of three subjects. These studies indicate that S. typhi ts 51-1 may be a suitable strain for the development of an improved oral typhoid fever vaccine. Studies are in progress to determine optimal methods of vaccine delivery preparatory to large phase 2 studies of efficacy.
Bellanti
J A
JA
Department of Pediatrics, Georgetown University School of Medicine, Washington, DC.
Zeligs
B J
BJ
Vetro
S
S
Pung
Y H
YH
Luccioli
S
S
Malavasic
M J
MJ
Hooke
A M
AM
Ubertini
T R
TR
Vanni
R
R
Nencioni
L
L
D000284:Administration, Oral; D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis*; D000920:Antibody-Dependent Cell Cytotoxicity; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008297:Male; D009154:Mutation; D012485:Salmonella typhi / Q000235:genetics / Q000276:immunology*; D013696:Temperature; D014436:Typhoid-Paratyphoid Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology
D000907:Antibodies, Bacterial; D014436:Typhoid-Paratyphoid Vaccines; D014613:Vaccines, Attenuated